Hyperlipidemia
Conditions
Brief summary
This study is intended to allow physicians to check the superior clinical efficacy of Vytorin compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement and cardiovascular risk reduction in adult patients with dislipidemia.
Interventions
ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
Sponsors
Organon and Co
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients Who Voluntary Accept To Participate In The Study After Been Informed By The Doctor And Signed The Informed Consent Form.
Exclusion criteria
* Any Another Kind Of Contraindication For Use Of Statins * Hypersensitivity To Any Of The Active Ingredients * Increased Serum Hepatic Enzymes (Over 3 Times Only) * Patients With Severe Hepatic Insufficiency * Women who are Pregnant or Potentially Pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the hypolipidemic effect of Vytorin after 4 weeks treatment in adult patients with mix dislipidemia to reduce the cardiovascular risk and achieve the ATP-III goals. | After 4 weeks treatment |
Secondary
| Measure | Time frame |
|---|---|
| To determine the capability of Vytorin to allow adults patients with dislipidemia and previously treated with atorvastatin to get further reduction of the cardiovascular risk and to achieve the ATP-III goals. | After 4 weeks treatment |
Outcome results
None listed